QIAGEN Acquires Intelligent Biosystems to Offer NGS Workflow
Intelligent Biosystems’ technology utilizes sequencing-by-synthesis chemistry and proprietary chemistries. Founded in 2005, the company released last fall the cost-effective MAX-Seq system, which was distributed by Azco BioTech, and announced the development of the PinPoint Mini for the clinical market. Bio-IT World reported that the PinPoint Mini, now known as the Mini-Seq, is designed for exome sequencing or sequencing of targeted genes. The Boston Herald reported in January that the company planned to sell the system for $85,000 and eventually seek FDA clearance. QIAGEN plans to release new automated sample preparation products for the sequencer and is developing workflows integrating its modular QIAsymphony automation family and low-throughput QIAcube system liquid handler. In 2011, molecular diagnostics accounted for 47% of QIAGEN sales.
Hilden, Germany and Germantown, MD 6/25/12—QIAGEN has announced the acquisition of next-generation sequencer (NGS) developer Intelligent Biosystems for an undisclosed amount. Further details of the acquisition were unavailable. QIAGEN disclosed the acquisition as part of a broader announcement of its entry into the NGS market. The company plans to launch a complete workflow for NGS, including sample preparation and bioinformatics, for clinical research and molecular diagnostics. For bioinformatics development, QIAGEN is partnering with SAP. “Our ambition is to create a new dimension of benefits for these technologies by offering workflow solutions for clinical use, particularly to develop new medicines and improve health care with advanced diagnostics,” stated QIAGEN CEO Peer M. Schatz. The workflow and sequencer are set to be released next year. The first tests to be offered will be eight preconfigured gene panels for cancer and customized panels. According to QIAGEN, the sequencer: can process up to 20 individual samples in parallel without pooling or barcoding; can be loaded with flow cells and reagents while it is in operation; and can process up to 20 different assay types in random order. QIAGEN expects the investments for the NGS portfolio to be dilutive to 2012 adjusted EPS by $0.01 and by $0.02 in 2013, but to be accretive to full-year results in 2014.
